Bipolar disorder is commonly misdiagnosed depending on the features that present, explained Stephanie Hsia, PharmD, MAEd, BCPP, of University of California, San Francisco.
Delayed diagnosis of bipolar disorder can occur when the condition is mistakenly identified as something else, said Stephanie Hsia, PharmD, MAEd, BCPP, associate professor of clinical pharmacy, University of California, San Francisco School of Pharmacy. The cost to patients is huge as they will get started on treatments that have no impact on their symptoms.
This transcript was lightly edited for clarity.
Transcript
What is typically the reason for misdiagnosis among patients with bipolar disorder?
Typically, patients are misdiagnosed with unipolar depression because patients with bipolar disorder actually spend most of their year in a depressive episode. So, when they present their primary care doctor will usually diagnose them with depression. That's the most common one. Then, I'd say the second most common would be that patients who have bipolar disorder with psychotic features will get misdiagnosed as [having] schizophrenia or schizoaffective disorder.
What is the impact on patients, and do we know the cost to the system when treatment is delayed or inappropriate treatment started?
The cost to patients is huge. Usually if they're misdiagnosed, treatment of unipolar depression and psychotic disorders is quite different than bipolar disorder. So, you can imagine if they get that misdiagnosis, they're going to be started on medications that don't work for them. Their symptoms aren't going to get better, they might start to lose some kind of confidence in the health care system, as well, and that can also lead to costs.
There's been studies that have shown that it can be hundreds of dollars a month, and I think there's one study where they looked at patients who hadn't been diagnosed and they had like a 170% increase in their costs following them over 6 years compared to somebody who does get that diagnosis. Yeah, it's pretty bad.
What are the implications of stigma on the treatment and management of bipolar disorder within diverse communities?
I would say stigma is huge. I think it's definitely a thing in a lot of different cultures, and it can really be a big barrier to someone being able to seek help. So, one, getting support from their family members or their community, but also in taking that next step and actually seeing a health care provider because it can be so stigmatized.
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More